{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:34:30Z","timestamp":1772588070823,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:00:00Z","timestamp":1477612800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Health Care and Philos"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11019-016-9743-0","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T04:48:40Z","timestamp":1477630120000},"page":"105-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Restoring a reputation: invoking the UNESCO Universal Declaration on Bioethics and Human Rights to bear on pharmaceutical pricing"],"prefix":"10.1007","volume":"20","author":[{"given":"Daniel J.","family":"Hurst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"9743_CR1","unstructured":"Access to Medicine Index. 2014. The Access to Medicine Index 2014. Accessed April 14, 2016. http:\/\/www.accesstomedicineindex.org\/sites\/2015.atmindex.org\/files\/2014_accesstomedicineindex_pricing_0.pdf ."},{"issue":"4","key":"9743_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2139\/ssrn.387860","volume":"6","author":"Paul A Argenti","year":"2004","unstructured":"Argenti, Paul A., and Bob Druckenmiller. 2004. Reputation and the corporate brand. Corporate Reputation Review 6(4): 368\u2013374. doi: 10.2139\/ssrn.387860 .","journal-title":"Corporate Reputation Review"},{"key":"9743_CR3","unstructured":"Baum, Stephanie. 2013. Survey finds lack of transparency drags down pharma reputation among patient groups. Accessed September 7, 2016. http:\/\/medcitynews.com\/2013\/01\/lack-of-transparency-drags-down-pharma-reputation-among-patient-groups-survey\/?rf=1 ."},{"key":"9743_CR5","unstructured":"Bluestone, Ken, Annie Heaton, and Christopher Lewis. 2002. Beyond philanthropy: The pharmaceutical industry, corporate social responsibility and the developing world. Ed. Bonita Glanville Morris. London: Oxfam."},{"key":"9743_CR6","unstructured":"Brigham, Alexander F., and Stefan Linssen. 2010. Your Brand Reputational Value Is Irreplaceable. Protect It! Forbes. Accessed April 14, 2016. http:\/\/www.forbes.com\/2010\/02\/01\/brand-reputation-value-leadership-managing-ethisphere.html ."},{"key":"9743_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1108\/S2051-503020140000016002","volume-title":"The UN global compact: Fair competition and environmental and labour justice in international markets","author":"Arzu \u00d6zs\u00f6zg\u00fcn \u00c7aliskan","year":"2015","unstructured":"\u00c7aliskan, Arzu \u00d6zs\u00f6zg\u00fcn. 2015. How UN global compact can contribute accountability and sustainability. In The UN global compact: Fair competition and environmental and labour justice in international markets, ed. Maria-Alejandra Gonzalez-Perez, and Liam Leonard, 17\u201336. Bingley: Emerald."},{"key":"9743_CR8","unstructured":"Chong, Mark. 2012. Importance of Corporate Reputation. The Business Times. Accessed April 14, 2016. http:\/\/ink.library.smu.edu.sg\/lkcsb_research\/3277\/ ."},{"key":"9743_CR9","unstructured":"Cohn, Jonathan. 2016. Drugs you don\u2019t need for disorders you don\u2019t have: Inside the pharmaceutical industry\u2019s campaign to put us all to sleep. The Huffington Post. Accessed April 14, 2016. http:\/\/highline.huffingtonpost.com\/articles\/en\/sleep-advertising\/ ."},{"issue":"1","key":"9743_CR10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1471-8847.00006","volume":"1","author":"Norman Daniels","year":"2001","unstructured":"Daniels, Norman. 2001. Social responsibility and global pharmaceutical companies. Developing World Bioethics 1(1): 38\u201341.","journal-title":"Developing World Bioethics"},{"key":"9743_CR11","unstructured":"DiJulio, Bianca, Jamie Firth, and Mollyann Brodio Follow. 2015. Kaiser health tracking poll: August 2015.\u201d The Henry J. Kaiser Family Foundation. Accessed April 14, 2016. http:\/\/kff.org\/health-costs\/poll-finding\/kaiser-health-tracking-poll-august-2015\/ ."},{"key":"9743_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-015-0100-5","author":"Hayley Droppert","year":"2015","unstructured":"Droppert, Hayley, and Sara Bennett. 2015. Corporate social responsibility in global health: An exploratory study of multinational pharmaceutical firms. Globalization and Health. doi: 10.1186\/s12992-015-0100-5 .","journal-title":"Globalization and Health"},{"key":"9743_CR13","unstructured":"Egan, Matt. 2016. How EpiPen came to symbolize corporate greed. CNN Money. Accessed September 7, 2016. http:\/\/money.cnn.com\/2016\/08\/29\/investing\/epipen-price-rise-history\/index.html ."},{"key":"9743_CR14","volume-title":"Bioindustry ethics","author":"David L Finegold","year":"2005","unstructured":"Finegold, David L., C\u00e9cile M. Bensimon, Abdallah S. Daar, Margaret L. Eaton, B\u00e9atrice Godard, Bartha Maria Knoppers, Jocelyn E. Mackie, and Peter A. Singer. 2005. Bioindustry ethics. Burlington, MA: Elsevier."},{"key":"9743_CR15","unstructured":"First, Harry. 2015. Unfair Drug Prices and Section\u00a05. NYU law and economics research paper no. 16-03. CPI Antitrust Chronicle November 2015 (2). Accessed April 14, 2016. http:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=2699843 ."},{"key":"9743_CR16","unstructured":"Fisher, William W., and Cyril P. Rigamonti. 2005. The South Africa AIDS controversy: A case study in patent law and policy. Harvard Law School. Accessed April 14, 2016. http:\/\/cyber.law.harvard.edu\/people\/tfisher\/South%20Africa.pdf ."},{"key":"9743_CR18","unstructured":"Friedman, Milton. 1970. The social responsibility of business is to increase its profits. The New York Times Magazine. Accessed April 14, 2016. http:\/\/www.mvopat.people.ysu.edu\/courses\/business_ethics\/business_ethics_readings\/Social_Responsibility_Friedman.pdf ."},{"key":"9743_CR17","unstructured":"Global Compact Self-Assessment Tool. Accessed September 7, 2016. http:\/\/www.globalcompactselfassessment.org ."},{"key":"9743_CR19","unstructured":"Goodfellow, Maya. 2015. Five times that big pharmaceutical companies have screwed over sick people more than Martin Shkreli. The Independent. Accessed April 14, 2016. http:\/\/www.independent.co.uk\/voices\/comment\/five-times-that-big-pharmaceutical-companies-have-screwed-over-sick-people-more-than-martin-shkreli-10515435.html ."},{"key":"9743_CR20","unstructured":"Harris Interactive. 2013. The Harris Poll 2013 RQ summary report. Accessed September 7, 2016. http:\/\/www.rankingthebrands.com\/PDF\/The%20Reputations%20of%20the%20Most%20Visible%20Companies%202013,%20Harris%20Interactive.pdf ."},{"key":"9743_CR21","unstructured":"Hesselbein, Frances. 2010. How did Peter Drucker see corporate responsibility? Harvard Business Review. Accessed April 14, 2016. https:\/\/hbr.org\/2010\/06\/how-did-peter-drucker-see-corp\/ ."},{"key":"9743_CR22","unstructured":"Hirschler, Ben. 2015. Exclusive\u2014Transatlantic divide: How U.S. pays three times more for drugs. Reuters. Accessed April 14, 2016. http:\/\/www.reuters.com\/article\/us-pharmaceuticals-usa-comparison-idUSKCN0S61KU20151012 ."},{"issue":"10","key":"9743_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMp1303723","volume":"369","author":"Hans V Hogerzeil","year":"2013","unstructured":"Hogerzeil, Hans V. 2013. Big Pharma and Social Responsibility\u2014The Access to Medicine Index. New England Journal of Medicine 369(10): 896\u2013899. doi: 10.1056\/NEJMp1303723 .","journal-title":"New England Journal of Medicine"},{"key":"9743_CR24","unstructured":"Hwang, Jung Joo. 2012. Is Merck\u2019s corporate social responsibility good for the global health? Accessed April 14, 2016. https:\/\/gps.ucsd.edu\/_files\/faculty\/gourevitch\/gourevitch_cs_hwang_jungjoo.pdf ."},{"issue":"10","key":"9743_CR25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt.3036","volume":"32","author":"Mark Kessel","year":"2014","unstructured":"Kessel, Mark. 2014. Restoring the pharmaceutical industry\u2019s reputation. Nature 32(10): 983\u2013990. doi: 10.1038\/nbt.3036 .","journal-title":"Nature"},{"key":"9743_CR26","first-page":"3","volume-title":"Globally responsible leadership: Managing according to the UN global compact","author":"Joanne T Lawrence","year":"2013","unstructured":"Lawrence, Joanne T. 2013. Responsible business: A brief perspective. In Globally responsible leadership: Managing according to the UN global compact, ed. Joanne T. Lawrence, and Paul W. Beamish, 3\u201319. Thousand Oaks, CA: SAGE Publication."},{"issue":"4","key":"9743_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5840\/beq200515440","volume":"15","author":"Klaus M Leisinger","year":"2005","unstructured":"Leisinger, Klaus M. 2005. The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly 15(4): 577\u2013594.","journal-title":"Business Ethics Quarterly"},{"key":"9743_CR28","unstructured":"Lewis, Neil A. 1999. U.S. Industry to drop AIDS drug lawsuit against South Africa. The New York Times. Accessed April 14, 2016. http:\/\/www.nytimes.com\/1999\/09\/10\/world\/us-industry-to-drop-aids-drug-lawsuit-against-south-africa.html ."},{"key":"9743_CR29","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511495359","volume-title":"Double standards in medical research in developing countries","author":"Ruth Macklin","year":"2004","unstructured":"Macklin, Ruth. 2004. Double standards in medical research in developing countries. Cambridge: Cambridge University Press."},{"key":"9743_CR30","volume-title":"The UNESCO universal declaration on bioethics and human rights: Background, principles and application","author":"Adolfo Mart\u00ednez-Palomo","year":"2009","unstructured":"Mart\u00ednez-Palomo, Adolfo. 2009. Article 14: Social responsibility and health. In The UNESCO universal declaration on bioethics and human rights: Background, principles and application, ed. Henk ten Have, and Michele S. Jean. Paris: UNESCO."},{"key":"9743_CR31","unstructured":"McNeil, Donald G. 2001. Oxfam joins campaign to cut drug prices for poor nations. The New York Times. Accessed April 14, 2016. http:\/\/www.nytimes.com\/2001\/02\/13\/world\/oxfam-joins-campaign-to-cut-drug-prices-for-poor-nations.html ."},{"key":"9743_CR32","unstructured":"M\u00e9decins Sans Fronti\u00e8res. 2014. Untangling the antiretroviral price reductions, 17th ed. Accessed April 14, 2016. https:\/\/www.msfaccess.org\/sites\/default\/files\/MSF_UTW_17th_Edition_4_b.pdf ."},{"key":"9743_CR33","unstructured":"Mill, John Stuart. 2001. Utilitarianism. Second edition. Ed. George Sher. Indianapolis: Hackett Publishing Company."},{"key":"9743_CR34","unstructured":"Mohammed, Rafi. 2015. It\u2019s time to rein in exorbitant pharmaceutical prices. Harvard Business Review. Accessed April 14, 2016. https:\/\/hbr.org\/2015\/09\/its-time-to-rein-in-exorbitant-pharmaceutical-prices ."},{"key":"9743_CR35","unstructured":"Mullin, Emily. 2015. Turing pharma says Daraprim availability will be unaffected by Shkreli Arrest. Forbes. Accessed April 14, 2016. http:\/\/www.forbes.com\/sites\/emilymullin\/2015\/12\/21\/turing-pharma-says-daraprim-availability-will-be-unaffected-by-shkreli-arrest\/#1dccb8c02e82 ."},{"key":"9743_CR38","unstructured":"OECD. 2008. Pharmaceutical pricing policies in a global market. OECD, Accessed April 14, 2016. http:\/\/apps.who.int\/medicinedocs\/documents\/s19834en\/s19834en.pdf ."},{"issue":"4","key":"9743_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1057\/palgrave.jmm.5050098","volume":"7","author":"Jane Parker","year":"2007","unstructured":"Parker, Jane. 2007. The reputation, image and influence of the pharmaceutical industry: Regaining credibility. Journal of Medical Marketing 7(4): 309\u2013313. doi: 10.1057\/palgrave.jmm.5050098 .","journal-title":"Journal of Medical Marketing"},{"key":"9743_CR39","unstructured":"Pfeffer, Jeffrey. 2009. Shareholders first? Not so fast\u2026. Harvard Business Review. Accessed April 14, 2016. https:\/\/hbr.org\/2009\/07\/shareholders-first-not-so-fast ."},{"key":"9743_CR40","unstructured":"Pollack, Andrew. 2015. Drug prices soar, prompting calls for justification. The New York Times. Accessed April 14, 2016. http:\/\/www.nytimes.com\/2015\/07\/23\/business\/drug-companies-pushed-from-far-and-wide-to-explain-high-prices.html?_r=0 ."},{"key":"9743_CR41","unstructured":"Read, Ian C. 2014. You gain respect in drops, but can lose it in gallons. Accessed April 14, 2016. https:\/\/www.linkedin.com\/pulse\/20140219125245-322581966-you-gain-respect-in-drops-but-can-lose-it-in-gallons ."},{"key":"9743_CR42","unstructured":"Reputation Institute. 2016. Pharmaceutical industry reputation in recovery as global pharma RepTrak\u00ae finds public perceptions improving. Accessed September 7, 2016. https:\/\/www.reputationinstitute.com\/CMSPages\/GetAzureFile.aspx?path=~%5Cmedia%5Cmedia%5Cmedia%5Cpress-release-for-2016-pharma-reptrak_final_052516.pdf&hash=2dc09d5d2f11f53cc1da33218e407ef49acc5024a5ed72028ebb4cf36157e9d0 ."},{"issue":"1","key":"9743_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1471-8847.00004","volume":"1","author":"David B Resnik","year":"2001","unstructured":"Resnik, David B. 2001. Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Developing World Bioethics 1(1): 11\u201332.","journal-title":"Developing World Bioethics"},{"key":"9743_CR44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/978-94-007-2512-6_128","volume-title":"Handbook of global bioethics","author":"David B Resnik","year":"2014","unstructured":"Resnik, David B. 2014. Scientific misconduct and research integrity. In Handbook of global bioethics, ed. Henk ten Have, and Bert Gordijn, 799\u2013810. Dordrecht: Springer."},{"key":"9743_CR45","volume-title":"Just business: Multinational corporations and human rights","author":"John Gerard Ruggie","year":"2013","unstructured":"Ruggie, John Gerard. 2013. Just business: Multinational corporations and human rights. New York: Norton."},{"key":"9743_CR46","volume-title":"Justice: What\u2019s the right thing to do?","author":"Michael J Sandel","year":"2009","unstructured":"Sandel, Michael J. 2009. Justice: What\u2019s the right thing to do?. New York: Farrar, Strauss, and Giroux."},{"key":"9743_CR47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-94-007-2512-6_77","volume-title":"Handbook of global bioethics","author":"Stefano Semplici","year":"2014","unstructured":"Semplici, Stefano. 2014. Social responsibility and health. In Handbook of global bioethics, ed. Henk ten Have, and Bert Gordijn, 187\u2013201. Dordrecht: Springer."},{"issue":"8","key":"9743_CR49","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/BF00872273","volume":"11","author":"Richard A Spinello","year":"1992","unstructured":"Spinello, Richard A. 1992. Ethics, pricing and the pharmaceutical industry. Journal of Business Ethics 11(8): 617\u2013626. doi: 10.1007\/BF00872273 .","journal-title":"Journal of Business Ethics"},{"key":"9743_CR50","unstructured":"Stossel, Thomas Peter. 2016. Prescription drug price controls pose lethal problems. American Enterprise Institute. Accessed April 14, 2016. http:\/\/www.aei.org\/publication\/prescription-drug-price-controls-pose-lethal-problems\/?utm_source=paramount&utm_medium=email&utm_content=AEITODAY&utm_campaign=032816?utm_source=twitter&utm_medium=social&utm_campaign=StosselDrugpricecontrols ."},{"key":"9743_CR51","doi-asserted-by":"crossref","DOI":"10.4324\/9781315648378","volume-title":"Global bioethics: An introduction","author":"Henk Have ten","year":"2016","unstructured":"ten Have, Henk. 2016. Global bioethics: An introduction. Abingdon, Oxon: Routledge."},{"key":"9743_CR52","unstructured":"The Economist. 2004. Two-faced capitalism. The Economist. Accessed April 14, 2016. http:\/\/www.economist.com\/node\/2369912 ."},{"key":"9743_CR53","unstructured":"The Economist. 2015. Pharmaceutical pricing: Crippling. The Economist. Accessed April 14, 2016. http:\/\/www.economist.com\/blogs\/democracyinamerica\/2015\/06\/pharmaceutical-pricing ."},{"key":"9743_CR54","unstructured":"The Economist. 2016. For my next trick\u2026. The Economist. March 26, 85\u201386."},{"key":"9743_CR55","unstructured":"The Wharton School. 2011. Profits and social responsibility: Chastened drug makers step up efforts to bring affordable medicines to poor countries. The Wharton School, University of Pennsylvania. Accessed April 14, 2016. http:\/\/knowledge.wharton.upenn.edu\/article\/profits-and-social-responsibility-chastened-drug-makers-step-up-efforts-to-bring-affordable-medicines-to-poor-countries\/ ."},{"key":"9743_CR56","doi-asserted-by":"crossref","unstructured":"UNESCO. 2010. Report of the international bioethics committee of UNESCO (IBC): On social responsibility and health. Paris: UNESCO.","DOI":"10.1515\/9783110208856.227"},{"key":"9743_CR57","unstructured":"UNESCO Universal Declaration on Bioethics and Human Rights. October 19, 2005."},{"key":"9743_CR58","unstructured":"United Nations. 2007. CSR and developing countries. Sustainable Development Innovation Briefs. Accessed August 15, 2016. https:\/\/sustainabledevelopment.un.org\/content\/documents\/no1.pdf ."},{"key":"9743_CR59","unstructured":"United Nations Global Compact. Our Strategy. Accessed April 14, 2016. https:\/\/www.unglobalcompact.org\/what-is-gc\/strategy ."},{"issue":"1","key":"9743_CR60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2307\/41166289","volume":"47","author":"Sushil Vachani","year":"2004","unstructured":"Vachani, Sushil, and N.Craig Smith. 2004. Socially responsible pricing: Lessons from the pricing of AIDS drugs in developing countries. California Management Review 47(1): 117\u2013144. doi: 10.2307\/41166289 .","journal-title":"California Management Review"},{"key":"9743_CR61","unstructured":"Yadav, Prashat. 2010. Differential pricing for pharmaceuticals: Review of current knowledge, new findings and ideas for action. Accessed April 14, 2016. http:\/\/apps.who.int\/medicinedocs\/documents\/s18390en\/s18390en.pdf ."}],"container-title":["Medicine, Health Care and Philosophy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-016-9743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11019-016-9743-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-016-9743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:55:45Z","timestamp":1657562145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11019-016-9743-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,28]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9743"],"URL":"https:\/\/doi.org\/10.1007\/s11019-016-9743-0","relation":{},"ISSN":["1386-7423","1572-8633"],"issn-type":[{"value":"1386-7423","type":"print"},{"value":"1572-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,28]]}}}